{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:48:20Z","timestamp":1778572100500,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81570836"],"award-info":[{"award-number":["81570836"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study investigated the factors influencing intravenous methylprednisolone pulse (IVMP) therapy for recovering visual acuity in Chinese patients with aquaporin-4 (AQP4) antibody-seropositive neuromyelitis optica-related optic neuritis (NMO-ON). This retrospective case series included 243 affected eyes of 182 patients (36 male, 146 female) diagnosed with NMO-ON in the Neuro-Ophthalmology Clinic of Beijing Tongren Hospital from September 2012 to September 2020. All patients with AQP4-antibody seropositivity had clinical manifestations of acute ON, excluding other diagnoses and received IVMP treatment at 500\u00a0mg\/day or 1000\u00a0mg\/day for 3\u00a0days. Primary outcome was the extent of improvement in logMAR visual acuity after IVMP treatment. The therapeutic influences of sex, age, baseline visual acuity, therapeutic intervals, and IVMP dose on acute NMO-ON were analysed. Chi-square tests, Mann\u2013Whitney U-tests, Kruskal\u2013Wallis tests, Spearman\u2019s correlation coefficients, and multiple linear regression were used for statistical analysis. Age ranged between 7 and 80\u00a0years (median age, 44; interquartile range [IQR], 29\u201352) years. Among the 243 eyes, the median improvement in logMAR visual acuity was 0.3 (IQR, 0\u20130.9). Therapeutic efficacy of IVMP was significantly higher in female than in male patients (<jats:italic>Z<\/jats:italic>\u2009=\u20092.117, <jats:italic>P<\/jats:italic>\u2009=\u20090.034). The treatment effect gradually decreased with increase in age at onset (<jats:italic>Rs<\/jats:italic>\u2009=\u20090.157, <jats:italic>P<\/jats:italic>\u2009=\u20090.015), and visual improvement was significantly lower in patients aged\u2009&gt;\u200950\u00a0years than in those\u2009\u2264\u200950\u00a0years (<jats:italic>Z<\/jats:italic>\u2009=\u20092.571, <jats:italic>P<\/jats:italic>\u2009=\u20090.010). When patients had low visual acuity at onset, improvements were more obvious (<jats:italic>rho<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.317, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); however, final visual acuity was still low <jats:italic>(rho<\/jats:italic>\u2009=\u20090.688, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Therapeutic effect was negatively correlated with therapeutic intervals (<jats:italic>rho<\/jats:italic>\u2009=\u20090.228, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Dosage of methylprednisolone (1000\u00a0mg\/day or 500\u00a0mg\/day) did not significantly influence treatment efficacy (<jats:italic>Z<\/jats:italic>\u2009=\u20090.951 <jats:italic>P<\/jats:italic>\u2009=\u20090.342). Therefore, IVMP therapy can improve visual acuity in the affected eyes of patients with AQP4 antibody-seropositive NMO-ON with similar effect at 500\u00a0mg\/day and 1000\u00a0mg\/day doses. Sex, age at onset, and therapeutic intervals may influence the efficacy of IVMP in patients with NMO-ON.<\/jats:p>","DOI":"10.1038\/s41598-021-01109-5","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:03:36Z","timestamp":1636974216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica"],"prefix":"10.1038","volume":"11","author":[{"given":"Sitong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364, 2106\u20132112 (2004).","journal-title":"Lancet"},{"key":"1109_CR2","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00415-017-8606-9","volume":"264","author":"H Kang","year":"2017","unstructured":"Kang, H. et al. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J. Neurol. 264, 2130\u20132140 (2017).","journal-title":"J. Neurol."},{"key":"1109_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00415-012-6594-3","volume":"260","author":"S Jarius","year":"2013","unstructured":"Jarius, S. & Wildemann, B. On the contribution of thomas clifford allbutt, F.R.S., to the early history of neuromyelitis optica. J. Neurol. 260, 100\u2013104 (2013).","journal-title":"J. Neurol."},{"key":"1109_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/1756285611398939","volume":"4","author":"N Collongues","year":"2011","unstructured":"Collongues, N. & de Seze, J. Current and future treatment approaches for neuromyelitis optica. Ther. Adv. Neurol. Disord. 4, 111\u2013121 (2011).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1109_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","volume":"17","author":"A Bruscolini","year":"2018","unstructured":"Bruscolini, A. et al. Diagnosis and management of neuromyelitis optica spectrum disorders\u2014An update. Autoimmun. Rev. 17, 195\u2013200 (2018).","journal-title":"Autoimmun. Rev."},{"key":"1109_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","volume":"13","author":"AT Toosy","year":"2014","unstructured":"Toosy, A. T., Mason, D. F. & Miller, D. H. Optic neuritis. Lancet Neurol. 13, 83\u201399 (2014).","journal-title":"Lancet Neurol."},{"key":"1109_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/OPTH.S28112","volume":"6","author":"JH Pula","year":"2012","unstructured":"Pula, J. H. & Macdonald, C. J. Current options for the treatment of optic neuritis. Clin. Ophthalmol. 6, 1211\u20131223 (2012).","journal-title":"Clin. Ophthalmol."},{"key":"1109_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud, H. et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult. Scler. 22, 185\u2013192 (2016).","journal-title":"Mult. Scler."},{"key":"1109_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K. & Bach, M. Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg visual acuity test (FrACT). Graefes Arch. Clin. Exp. Ophthalmol. 247, 137\u2013142 (2009).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"1109_CR10","volume-title":"Consultation on Development of Standards for Characterization of Vision Loss and Visual Function","author":"WHO","year":"2003","unstructured":"WHO. Consultation on Development of Standards for Characterization of Vision Loss and Visual Function (WHO, 2003)."},{"key":"1109_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel, K., Feltgen, N., Burau, H., Hansen, L. & Bach, M. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg visual acuity test. Investig. Ophthalmol. Vis. Sci. 47, 1236\u20131240 (2006).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"1109_CR12","first-page":"1176","volume":"69","author":"MA Mealy","year":"2012","unstructured":"Mealy, M. A., Wingerchuk, D. M., Greenberg, B. M. & Levy, M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch. Neurol. 69, 1176\u20131180 (2012).","journal-title":"Arch. Neurol."},{"key":"1109_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","volume":"286","author":"DM Wingerchuk","year":"2009","unstructured":"Wingerchuk, D. M. Neuromyelitis optica: Effect of gender. J. Neurol. Sci. 286, 18\u201323 (2009).","journal-title":"J. Neurol. Sci."},{"key":"1109_CR14","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello, M. et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70, 2197\u20132200 (2008).","journal-title":"Neurology"},{"key":"1109_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius, S. et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J. Neuroinflamm. 9, 14 (2012).","journal-title":"J. Neuroinflamm."},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/1352458515617248","volume":"22","author":"R Yamasaki","year":"2016","unstructured":"Yamasaki, R. et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult. Scler. 22, 1337\u20131348 (2016).","journal-title":"Mult. Scler."},{"key":"1109_CR17","doi-asserted-by":"publisher","first-page":"585471","DOI":"10.3389\/fneur.2020.585471","volume":"11","author":"B Chen","year":"2020","unstructured":"Chen, B. et al. Predictive factors of resistance to high-dose steroids therapy in acute attacks of neuromyelitis optica spectrum disorder. Front. Neurol. 11, 585471 (2020).","journal-title":"Front. Neurol."},{"key":"1109_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fneur.2020.00932","volume":"11","author":"T Akaishi","year":"2020","unstructured":"Akaishi, T. et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front. Neurol. 11, 932 (2020).","journal-title":"Front. Neurol."},{"key":"1109_CR19","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish, H. et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol. Neuroimmunol. Neuroinflamm. 6, e572 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1109_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00415-015-7766-8","volume":"262","author":"M Krumbholz","year":"2015","unstructured":"Krumbholz, M. et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J. Neurol. 262, 1379\u20131384 (2015).","journal-title":"J. Neurol."},{"key":"1109_CR21","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/1352458513515085","volume":"20","author":"N Collongues","year":"2014","unstructured":"Collongues, N. et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult. Scler. 20, 1086\u20131094 (2014).","journal-title":"Mult. Scler."},{"issue":"1","key":"1109_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","volume":"10","author":"DM Wingerchuk","year":"2008","unstructured":"Wingerchuk, D. M. & Weinshenker, B. G. Neuromyelitis optica. Curr. Treat Options Neurol. 10(1), 55\u201366 (2008).","journal-title":"Curr. Treat Options Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01109-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01109-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:28:43Z","timestamp":1670088523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01109-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01109-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22229"}}